Last reviewed · How we verify
Tislelizumab with Fruquintinib, Metronidazole
Tislelizumab with Fruquintinib, Metronidazole is a Small molecule drug developed by Jing-yuan Fang, MD, Ph. D. It is currently in Phase 2 development.
At a glance
| Generic name | Tislelizumab with Fruquintinib, Metronidazole |
|---|---|
| Sponsor | Jing-yuan Fang, MD, Ph. D |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tislelizumab with Fruquintinib, Metronidazole CI brief — competitive landscape report
- Tislelizumab with Fruquintinib, Metronidazole updates RSS · CI watch RSS
- Jing-yuan Fang, MD, Ph. D portfolio CI
Frequently asked questions about Tislelizumab with Fruquintinib, Metronidazole
What is Tislelizumab with Fruquintinib, Metronidazole?
Tislelizumab with Fruquintinib, Metronidazole is a Small molecule drug developed by Jing-yuan Fang, MD, Ph. D.
Who makes Tislelizumab with Fruquintinib, Metronidazole?
Tislelizumab with Fruquintinib, Metronidazole is developed by Jing-yuan Fang, MD, Ph. D (see full Jing-yuan Fang, MD, Ph. D pipeline at /company/jing-yuan-fang-md-ph-d).
What development phase is Tislelizumab with Fruquintinib, Metronidazole in?
Tislelizumab with Fruquintinib, Metronidazole is in Phase 2.